Development of a Specific Diagnostic Test for Measurement of β-Amyloid (1-42) [βA4(l-42)] in CSF

  • H. Vanderstichele
  • K. Blennow
  • N. D’Heuvaert
  • M.-A. Buyse
  • A. Wallin
  • N. Andreasen
  • P. Seubert
  • A. Van de Voorde
  • E. Vanmechelen

Abstract

Alzheimer’s disease (AD) is considered as the most important of all neurodegenerative diseases, due to its frequent occurrence and devastating consequences. AD appears to be a very heterogeneous group of disorders sharing clinical characteristics and pathological hallmarks. Neuropathologically, the brains of AD patients are characterized by the presence of intracellular accumulations of neurofibrillary tangles (primarily composed of a hyperphosphorylated form of the microtubule associated protein tau) in the hippocampus and temporal lobe of the cerebral cortex, the extracellular deposition of amyloid fibrils in the senile plaques, and the degeneration of neurons and their synapses. Neither plaques or tangles are restricted to AD (Selkoe, 1991).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Blennow, K., Fredman, P., Wallin, A., Gottfries, C.-G., Längström, L., Svennerholm, L., 1993, Protein analyses in cerebrospinal fluid: I. Influence of concentration gradients for proteins on cerebrospinal fluid/serum albumin ratio. Eur. Neurol 33:126.PubMedCrossRefGoogle Scholar
  2. Citron, M., Vigo-Pelfrey, C., Teplow, D. B., Miller, C., Schenk, D., Johnston, J., Winblad, B., Venizelos, N., Lannfelt, L., Selkoe, D. J., 1994, Excessive production of amyloid β-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation. Proc. Natl. Acad. Sci. 91:11993.PubMedCrossRefGoogle Scholar
  3. Citron, M., Westaway, D., Xia, W., Carlson, G., Diehl, T., Levesque, G., Johnson-Wood, K., Lee, M., Seubert, P., Davis, A., Kholodenko, D., Motter, R., Sherrington, R., Perry, B., Yao, H., Strome, R., Lieberburg, I., Rommens, J., Kim, S., Schenk, D., Fraser, P., St George Hyslop, P., Selkoe, D.J., 1997, Mutant presenilins of Alzheimer’s Disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice. Nature Med, 3:67.PubMedCrossRefGoogle Scholar
  4. Johnston, J. A., Cowburn, R. F., Norgren, S., Wiehager, B., Venizelos, N., Winblad, B., Vigo-Pelfrey, C., Schenk, D., Lannfelt, L., O’Neill, C., 1994, Increased β-amyloid release and levels of amyloid precursor protein (APP) in fibroblast cell lines from family members with the Swedish Alzheimer’s disease APP670/671 mutation. FEBS Lett. 354:274.PubMedCrossRefGoogle Scholar
  5. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., 1984, Clinical diagnosis of Alzheimer’s disease: Report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer’s disease. Neurology 34:939.PubMedCrossRefGoogle Scholar
  6. Motter, R., Vigo-Pelfrey, C., Kholodenko, D., Barbour, R., Johnson-Wood, K., Galasko, D., Chang, L., Miller, B., Clark, C., Green, R., Olson, D., Southwick, P., Wolfert, R., Munroe, B., Lieberburg, I., Seubert, P., Schenk, D.,1995, Reduction of β-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer’s Disease. Ann. Neurol. 38:643.PubMedCrossRefGoogle Scholar
  7. Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T.D., Hardy, J., Hutton, M., Kukull, W, Larson, E., Levy-Lahad, E., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D., Younkin, S., 1996, Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer’s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer’s disease. Nature Med. 2:864.PubMedCrossRefGoogle Scholar
  8. Selkoe, D.J., 1996, Amyloid β-protein and the genetics of Alzheimer’s disease. J. Biol. Chem. 217:18295.Google Scholar
  9. Tamaoka, A., Sawamura, N., Fukushima, T., Shoji, S., Matsubara, E., Shoji, M., Hirai, S., Furiya, Y., Endoh, R., Mori, H., 1997, Amyloid β protein 42(43) in cerebrospinal fluid of patients with Alzheimer’s disease. J. Neurol. Sci. 148:41.PubMedCrossRefGoogle Scholar
  10. Vanmechelen, E., Blennow, K., Davidsson, P., Cras, P., Van De Voorde, A., 1997, Combination of tau/phospho-tau with other biochemical markers for Alzheimer cerebrospinal fluid diagnosis and tau in cerebrospinal fluid as marker for neurodegeneration, In: Alzheimer’s disease: Biology, Diagnosis and Therapeutics, Iqbal, K., Winblad, B., Nishimura, T., Takeda, M., Wisniewski, H.M., eds., John Wiley and Sons, Chichester:197.Google Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • H. Vanderstichele
    • 1
  • K. Blennow
    • 2
  • N. D’Heuvaert
    • 1
  • M.-A. Buyse
    • 1
  • A. Wallin
    • 2
  • N. Andreasen
    • 3
  • P. Seubert
    • 4
  • A. Van de Voorde
    • 1
  • E. Vanmechelen
    • 1
  1. 1.Innogenetics NVGhentBelgium
  2. 2.Department of Clinical NeuroscienceUniversity of Göteborg Sahlgrenska University HospitalMölndalSweden
  3. 3.Department of RehabilitationPiteå RiverValley HospitalPiteåSweden
  4. 4.Athena NeurosciencesSouth San FranciscoUSA

Personalised recommendations